Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)
A Phase 3, Open-Label Period Followed by a Randomized, Double-blind, Placebo-controlled Study of the Analgesic Efficacy of Extended-release Hydrocodone/Acetaminophen (Vicodin CR) Compared to Placebo in Subjects With Chronic Low Back Pain
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Arizona
-
Tempe, Arizona, United States, 85282
- Site Reference ID/Investigator# 10143
-
Tempe, Arizona, United States, 85282
- Site Reference ID/Investigator# 10161
-
Tucson, Arizona, United States, 85741
- Site Reference ID/Investigator# 10155
-
-
California
-
Anaheim, California, United States, 92801
- Site Reference ID/Investigator# 10160
-
Lomita, California, United States, 90717
- Site Reference ID/Investigator# 10821
-
-
Florida
-
Clearwater, Florida, United States, 33765
- Site Reference ID/Investigator# 10152
-
DeLand, Florida, United States, 32720
- Site Reference ID/Investigator# 10157
-
Oldsmar, Florida, United States, 34677
- Site Reference ID/Investigator# 10142
-
Pembroke Pines, Florida, United States, 33024
- Site Reference ID/Investigator# 10147
-
Plantation, Florida, United States, 33324
- Site Reference ID/Investigator# 13821
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Site Reference ID/Investigator# 15821
-
-
Kentucky
-
Crestview Hills, Kentucky, United States, 41017
- Site Reference ID/Investigator# 10136
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70114
- Site Reference ID/Investigator# 10822
-
Shreveport, Louisiana, United States, 71103
- Site Reference ID/Investigator# 10140
-
-
Massachusetts
-
Brockton, Massachusetts, United States, 02301
- Site Reference ID/Investigator# 10158
-
Fall River, Massachusetts, United States, 02720
- Site Reference ID/Investigator# 13601
-
Wellesley Hills, Massachusetts, United States, 02481-2106
- Site Reference ID/Investigator# 10162
-
-
Nebraska
-
Omaha, Nebraska, United States, 68134
- Site Reference ID/Investigator# 10159
-
-
Nevada
-
Las Vegas, Nevada, United States, 89144
- Site Reference ID/Investigator# 10126
-
-
Ohio
-
Cincinnati, Ohio, United States, 45227
- Site Reference ID/Investigator# 10156
-
Cincinnati, Ohio, United States, 45242
- Site Reference ID/Investigator# 10148
-
Kettering, Ohio, United States, 45429
- Site Reference ID/Investigator# 10151
-
Marion, Ohio, United States, 43302
- Site Reference ID/Investigator# 10138
-
Perrysburgh, Ohio, United States, 43554
- Site Reference ID/Investigator# 10150
-
-
Texas
-
Dallas, Texas, United States, 75251
- Site Reference ID/Investigator# 10141
-
El Paso, Texas, United States, 79902
- Site Reference ID/Investigator# 10149
-
Fort Worth, Texas, United States, 76135
- Site Reference ID/Investigator# 10130
-
Killeen, Texas, United States, 76543
- Site Reference ID/Investigator# 10163
-
San Antonio, Texas, United States, 78209-1744
- Site Reference ID/Investigator# 13201
-
San Antonio, Texas, United States, 78229
- Site Reference ID/Investigator# 10154
-
-
Virginia
-
Roanoke, Virginia, United States, 24018
- Site Reference ID/Investigator# 10144
-
-
Washington
-
Spokane, Washington, United States, 99204
- Site Reference ID/Investigator# 10113
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult male and female subjects who voluntarily sign the informed consent
- Diagnosis of CLBP of 6 months duration
Exclusion Criteria:
- Incapacitated or bedridden subjects
- Subjects with history of surgical or invasive intervention
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Open-label ABT-712
2 ABT-712 extended-release tablets, twice daily, for up to 3 weeks (open-label period).
|
ABT-712 extended-release tablet
Other Names:
|
|
Experimental: Double-blind ABT-712
2 ABT-712 extended-release tablets, twice daily, for 4 weeks (double-blind period).
|
ABT-712 extended-release tablet
Other Names:
|
|
Placebo Comparator: Double-blind Placebo
2 placebo tablets, twice daily, for 4 weeks (double-blind period).
|
Placebo tablet
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Double-blind (DB) Baseline to Final Assessment in Chronic Lower Back Pain (CLBP) Intensity by Visual Analog Scale (VAS)
Time Frame: Double-blind baseline to 4 weeks
|
The change from the DB randomization baseline (DB baseline: the last assessment before first dose in the DB period) to the final assessment in pain intensity, assessed using the CLBP Intensity VAS (0 mm = No Pain and 100 mm = Worst Pain Imaginable).
Least squares means and standard errors from 2-way ANCOVA model without interaction.
|
Double-blind baseline to 4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Double-blind (DB) Baseline to Final Assessment in Chronic Pain Sleep Inventory (CPSI)
Time Frame: Double-blind baseline to 4 weeks
|
The change from the DB randomization baseline (DB baseline: the last assessment before first dose in the DB period) to the final assessment of the impact of pain on the participant's sleep.
The CPSI utilizes a 100 mm VAS scale for questions of how often the participant had trouble falling asleep because of pain, needed sleeping medication, was awakened by pain during the night, and was awakened by pain in the morning (0 mm = Never and 100 mm = Always); and for rating the overall quality of sleep (0 mm = Very Poor and 100 mm = Excellent).
Least squares means and standard errors from 2-way ANCOVA model without interaction.
|
Double-blind baseline to 4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Back Pain
- Low Back Pain
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Antipyretics
- Analgesics, Opioid
- Narcotics
- Respiratory System Agents
- Antitussive Agents
- Acetaminophen
- Hydrocodone
Other Study ID Numbers
Other Study ID Numbers
- M10-385
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.